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Objective.When pathologic discrepancyarisesbetween high-gradecytologyonPapanicolaou (Pap)smearandlow-gradehistology
on cervical biopsy, Loop Electrosurgical Excisional Procedure (LEEP) is one management alternative. Our objective was to
determine whether the time from initial HGSIL Pap to LEEP aﬀects the pathologic grade of the LEEP specimen. Study Design.
We performed a retrospective case-control study identifying LEEPs performed for discrepancy over a 10-year period (1997–2007).
121 subjects were separated into two groups based on LEEP pathology (≤ CIN 1 and CIN 2,3) and compared using χ2. Results.
Of the 121 LEEP specimens, 67 (55.4%) had CIN 2,3. CIN 2,3 was more often discovered when LEEP was performed within 3
months of the HGSIL Pap smear versus after 5 months (55.2% versus 16.4%, P = .096). Conclusion. Women undergoing LEEP for
discrepancy >5 months from their HGSIL Pap demonstrated a trend toward less CIN 2,3 on LEEP pathology.
1.Introduction
Women with high-grade Papanicolaou (Pap) smears have a
43%–66% risk of having moderate- to high-grade intraep-
ithelial neoplasia (CIN 2 or CIN 3) on subsequent biopsy
and a 2% risk of having invasive cancer [1]. However,
when discrepancies occur between Pap smear cytology
and cervical biopsy histology, this can cause a clinical
dilemma. We deﬁne discrepancy as patients with High-
Grade Squamous Intraepithelial Lesion (HGSIL) Pap smear
followed by cervical biopsies with Cervical Intraepithelial
Neoplasia (CIN) 1 histology or less. In cases of discrepancy,
theAmericanSocietyforColposcopyandCervicalPathology
(ASCCP) previously favored an excisional procedure for
diagnosis in nonpregnant patients when no lesion or CIN1
is identiﬁed with satisfactory colposcopy [2]. As we develop
a better understanding of HPV infection, its clinical course,
and prognosis, more people are considering conservative
management. The most recent ASCCP guidelines in 2006
included the option of repeating Pap smear and colposcopy
every6monthsfor1yearinwomenover20withdiscrepancy
and recommended this conservative monitoring pathway in
the adolescent population [3].
In nonadolescent patients, a loop electrosurgical exci-
sional procedure (LEEP) is a reasonable management option
for discrepancy, as there is a concern that the high-grade
lesionfoundonPapsmearwasmissedonthecolposcopically
directed biopsy. However, we know that as many as 35%
of women with HGSIL will regress spontaneously, making
the excisional procedure unnecessary [4]. Data evaluating
the time from the initial HGSIL cytology to the LEEP, as
it impacts likelihood of ﬁnding signiﬁcant pathology in
the LEEP specimen, has not been well characterized. Our
objective was to determine whether the time from initial
HGSIL Pap to LEEP, when done for discrepancy, aﬀects
the pathologic grade of CIN in the LEEP specimen. We
hypothesized that, as the time interval between the initial
HGSIL Pap and subsequent LEEP for discrepancy increased,
the likelihood of ﬁnding CIN 2-3 in the LEEP specimen
would decrease.2 Obstetrics and Gynecology International
2.MaterialsandMethods
Thiswasaretrospectivecase-controlstudyofallLEEPproce-
dures done for discrepancy at the University of Washington
Medical Center and Harborview Medical Center in Seattle,
Washington. We identiﬁed potential cases by performing
a search in the pathology database to identify all LEEP
specimens between January 1, 1997 and August 31, 2007.
Of note, the Dysplasia Clinics at these two medical centers
serve as referral centers for women diagnosed with abnormal
cytology at local clinics. Thus, not all initial Pap smears
originated from these two medical centers. In the two
Dysplasia Clinics, a standardized colposcopy form is used
to record impression and results of colposcopy, but the Pap
smear is not routinely repeated, nor do we have a complete
history of prior Pap smears. Based on colposcopic ﬁndings,
biopsies were performed at the discretion of the attending
physician.
TodeterminewhichLEEPsweredonefordiscrepancy,we
linked all LEEPs with their respective preceding Pap smear,
colposcopyreport,andcervicalbiopsyresult.Weincludedall
women, 18–49 years old, who had pathologic discrepancy as
deﬁned by HGSIL Pap smear and a subsequent colposcopy
with cervical biopsies of CIN 1 or less. We excluded
those who had an unsatisfactory colposcopy exam, previous
excisionalprocedure,andpositiveendocervicalcurettageand
those who were pregnant or HIV positive.
Once discrepant cases were identiﬁed, we performed
a chart review and used a standardized data collection
instrument to gather general demographic information and
risk factors associated with progression of cervical neoplasia
(smoking, number of partners, age of coitarche, history of
sexually transmitted infections, and birth control method).
On this form we also documented cytologic and histologic
results of the Pap smear, cervical biopsy, and LEEP proce-
dure, and recorded the length of time between the Pap smear
and the LEEP.
A power calculation was based on the assumption that,
in LEEPs done for discrepancy, the prevalence of CIN 2
or 3 found in the LEEP specimen will be higher when the
LEEP was performed closer to the time of the HGSIL Pap.
We divided the time intervals from Pap smear to LEEP into
three intervals: less than three months, between three and
ﬁve months, and greater than ﬁve months. As this was a
retrospective study, we used our data of 55% prevalence of
CIN 2,3 in LEEP specimens when the time interval from
the Pap smear to the LEEP is less then 3 months and 16%
when the interval is greater than ﬁve months. From this, the
calculated sample size was 23 women to give 80% power
and α = 0.05 to detect this diﬀerence in pathologic result,
demonstrating that the study was appropriately powered to
test our hypothesis.
Based on their LEEP histology, subjects were separated
into two groups: CIN 1 or less and CIN 2,3. The “CIN 1 or
less”groupincludednormal,cervicitis,andCIN1.The“CIN
2,3” group included CIN 2 and CIN 3. We chose these two
groups based on clinical application, as this is the general
division that determines treatment management. Statistical
analysis was executed with SPSS v.16. Diﬀerences between
the two groups were examined using Student’s t-test and χ
2.
Univariate and multivariate logistic regressions were used to
calculate odds ratios and 95% conﬁdence intervals for the
association between time since HGSIL and histologic grade
of LEEP.
This study was approved by the International Review
Board at the University of Washington, IRB Application
Number 07-8885-E/A 01.
3. Results
Of the 1,356 patients who underwent a LEEP during this
time period, 157 were performed for discrepancy. Of these,
36 women were excluded: 24 had unsatisfactory colposcopy,
six had endocervical curettings positive for neoplasia, four
were HIV positive, and two were older than 49. The 121
remaining patients were divided into two groups based on
the pathologic grade of CIN in their LEEP specimen (CIN
1o rC I N2 , 3 ) .A sd e m o n s t r a t e db yTable 1, the two groups
were similar with regard to age, ethnicity, parity, tobacco
use, coitarche, number of partners, and history of sexually
transmitted infections. There was a diﬀerence noted in the
use of birth control method, likely due to the number of
Depo-Provera users in the CIN 2,3 group.
Of the 121 patients who underwent a LEEP for dis-
crepancy, 67 patients (55.4%) had CIN 2,3 on their LEEP
pathology specimen and 54 (44.6%) had CIN 1 or less. We
examinedthetimeintervalfromtheinitialHGSILPapsmear
to the LEEP procedure in the CIN 2,3 group. Of the 67 who
had CIN 2,3 on LEEP histology, 37 (55.2%) had their LEEP
within three months of the initial Pap versus 11 (16.4%) who
had their LEEP greater than ﬁve months after the Pap smear
(Figure 1). Although there was no signiﬁcant diﬀerence in
thetimeintervalbetweenthegroups,thePearsoncorrelation
coeﬃcient, a measure of linear trend, was −0.15 (P =
.096). Though not statistically signiﬁcant, this suggests a
trend toward decreased prevalence of CIN 2,3 in the LEEP
specimen as the time from HGSIL Pap smear increased. In
order to explore this further, a univariate logistic regression
was performed to test for trend of LEEP histology over time
using CIN 2,3 as the outcome (Table 2). In this regression as
time interval increased, the likelihood of CIN 2,3 decreased,
though the eﬀect did not reach statistical signiﬁcance.
Although it was not our initial intent to examine the
eﬀect of birth control method on the histologic grade of
the LEEP specimens, there was a signiﬁcant diﬀerence in
the use of Depo-Provera between women with low-grade
and moderate- or high-grade CIN (3.8% in CIN 1 versus
15.2% in CIN 2,3). We therefore performed a multivariate
regression using the covariates of time interval and birth
control method to analyze the eﬀect of birth control method
on dysplasia (Table 3). Birth control method was divided
into three groups: nonhormonal users (no method, tubal
ligation, barrier methods, and Copper IUD), estrogen and
progesterone combined methods (oral contraceptive pills,
NuvaRing, patch), and progesterone only methods (Depo-
Provera). Depo-Provera users were more likely to have CIN
2,3 in their LEEP specimen (OR 7.59, P = .02).Obstetrics and Gynecology International 3
Table 1: Demographic characteristics comparing women with CIN 1 or CIN 2,3 on LEEP.
Characteristic C I N1o rl e s s C I N2 - 3 P
n = 54 (%) n = 67 (%)
Age: (years) ± SD 28.2 ± 8.7 27.2 ± 5.7 .46
a
Ethnicity Caucasian 35 (66) 37 (55) .48b
African American 5 (9) 5 (8)
Hispanic 4 (8) 9 (13)
Asian 6 (11) 7 (10)
Other/Unknown 4 (6) 9 (13)
Parity 0 36 (67) 38/65 (59) .06b
1 13 (24) 8/65 (12)
2 2 (4) 13/65 (20)
>23 ( 6 ) 6 / 6 5 ( 9 )
Tobacco None 41 (76) 46 (69) .10b
<1ppd 12 (23) 11 (16)
1p p d 1( 2 ) 8( 1 2 )
2p p d 0( 0 ) 2( 3 )
Coitarche: (years) ± SD 16.6 ± 2.0 16.5 ± 2.2 .81a
No. of Partners <5 25/49 (51) 22/58 (38) .17b
>5 24/49 (49) 36/58 (62)
History of STIs None 39/51 (77) 44/65 (68) .92b
CT 3/51 (6) 7/65 (11)
GC 0/51 (0) 1/65 (2)
Genital Herpes 2/51 (4) 3/65 (5)
Genital Warts 2/51 (4) 3/65 (5)
PID 1/51 (2) 1/65 (2)
More than 1 4/51 (8) 6/65 (9)
BCM None 8/52 (15) 1/66 (2) .01b
Condoms 7/52 (14) 6/66 (9)
Oral Contraceptive Pills 31/52 (60) 44/66 (67)
Depo-Provera 2/52 (4) 10/66 (15)
NuvaRing 1/52 (2) 1/66 (2)
Patch 3/52 (6) 0 (0)
BTL 0/52(0) 3/66 (5)
Copper IUD 0/52 (0) 1/66 (2)
Denominators may vary due to missing data.
aStudent’s t-test,
bChi-square.
Table 2: Univariate logistic regression of time interval and CIN 2,3
in LEEP.
Time interval (categorical) CIN 2,3 in LEEP
OR (95% CI) P
<3 months 1.0 (Reference) —
3–5 months 0.63 (0.27–1.44) .27
>5 months 0.47 (0.18–1.21) .12
Becauseofthissigniﬁcantrelationship,weperformedthe
multivariate regression in the CIN 2,3 group controlling for
contraceptive method. After controlling for the birth control
variable, we demonstrated a trend toward fewer CIN 2,3
LEEPﬁndingswhentheprocedurewasperformedmorethan
ﬁve months from the HGSIL Pap, a trend that neared but did
not achieve signiﬁcance (OR 0.39, P = .07).
4. Discussion
This study was initiated prior to the 2006 ASCCP Consensus
Guidelines, which were released in October 2007. New
changes announced in the guidelines included those that
direct the management of abnormal cytology in adolescents
of 20 years and younger. For adolescents in the discrepant
situation, it is now recommended that they be observed
and monitored with Pap smears and colposcopy exami-
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Figure 1: Subjects were divided into two groups by their LEEP
histology (CIN 1 or CIN 2,3), and we examined the time interval
from their HGSIL Pap to their LEEP. The blue bars signify those
subjects who had their LEEP done less than 3 months from the
HGSIL Pap. The red bars are those who had their LEEP 3–5 months
from the HGSIL Pap. The green bars are those who had their LEEP
after 5 months of the HGSIL Pap.
Table 3: Univariate logistic regression with birth control method
and CIN 2,3 in LEEP.
Variable CIN 2,3 in LEEP
OR (95% CI) P
Birth control method
None/non-hormonal 1.0 (Reference) —
Estrogen + Progesterone 1.83 (0.73–4.58) 0.20
Progesterone only 7.59 (1.34–43.2) 0.02
management in this group has been favored, as we know
that the majority of HPV infections will clear without
treatmentwithintwoyearsandhavenegligiblelong-standing
clinical signiﬁcance [5]. In addition, although generally well
tolerated, LEEPs are not without complications, including
risks to future pregnancies such as premature delivery,
premature rupture of membranes, and low birth weight [6–
8].Wedidnotexamineadolescentsseparatelyinthisstudyas
there were only 14 subjects that were 20 years or younger at
the time of their LEEP. However, our results suggest that the
cautious approach in treating adolescents that the ASCCP is
now advising is not detrimental.
The role of exogenous estradiol and progesterone in
the development of cervical cancer has been discussed
extensively. There is still insuﬃcient data as to whether oral
contraceptive pills are associated with the development of
cervical cancer in HPV-infected women [9]. Thomas et al.
showed an increase risk of CIN 3 but not invasive carcinoma
in Depo-Provera users, a risk that increased with the length
of use [10]. Many have examined the immunohistochemical
Table 4: Multivariate Regression of Time Interval and CIN 2,3
controlling for Birth Control Method.
Variable CIN 2,3 in LEEP
OR (95% CI) P
Time interval (categorical)
<3 months (Reference) —
3–5 months 0.66 (0.27–1.59) 0.35
>5 months 0.39 (0.14–1.07) 0.07
presence of estrogen and progesterone receptors within the
cervix and compared the makeup of receptors in normal
cervix with those that contain neoplasia [11]. Konishi et al.
have suggested that HPV infection may increase proges-
teronereceptorexpressionthatisfoundinneoplasticcervical
squamous cells [12]. Progesterone has been hypothesized to
be a modulator of the immune system [13]. In this way,
the exposure to Depo-Provera may decrease the clearance
of HPV infection. However, the use of hormonal birth
control was not the focus of this study, and as a result
this study was not powered to examine this association.
Still, this is an intriguing ﬁnding that may merit further
investigation.
One limitation of our study is that the University of
Washington and Harborview Medical Centers are referral
centers for cervical neoplasia. As many patients are referred
from providers outside the system, original Pap smears are
notalwaysavailabletoustoconﬁrmtheHGSILnoristhePap
smear routinely repeated at the time of colposcopy. Studies
demonstrate that pathologists vary in their determination of
cytologic grading of Pap smears [14]. If there is a tendency
to err on side of overcalling the Pap smear HGSIL and the
patient has a colposcopy consistent with CIN1 or less, this
would lead to discrepancy. A LEEP done in this scenario
would likely have lower-grade CIN than in a situation where
a pathologist is more likely to read LGSIL on the original Pap
smear.
Another limitation of this study is the inherent disad-
vantage of inter observer variation on colposcopy exami-
nation because, in our clinics, multiple providers perform
colposcopy. We know that colposcopy is imperfect and up
to 33% of CIN 2,3 can be missed on a single colposcopy
examination [15]. Missing the diagnosis of CIN 2,3 on
colposcopy and cervical biopsies after an HGSIL pap smear
places the patient in a discrepant situation and previously
obligated them to a LEEP. However, this would likely have
given us a higher number of CIN 2,3 on LEEP histology,
as it may have been present but missed on the preceding
colposcopy examination.
In addition, we used medical records of LEEP pathology
to identify cases of discrepancy. This may open the potential
of selection bias as some cases could be missed, or inadver-
tently miscoded. These LEEPs were identiﬁed, though, as a
pathology database, and Table 1 shows that our two groups
were similar.
Finally, our examination of birth control method as it
aﬀected the LEEP pathology was not adequately investigated.Obstetrics and Gynecology International 5
There are many subtle eﬀects of birth control on cervical
dysplasia. We grouped non-hormonal methods together,
when in fact this may represent a heterogeneous group of
women. Women who are using no method may or may not
be abstaining from intercourse. Those that are abstaining
may have less exposure to HPV, which could lead to a higher
rate of HPV regression. In the same way, we would expect
c o n d o mu s e r st oh a v el e s se x p o s u r et oH P Va sW i n e re ta l .
have shown that condoms prevent HPV transmission [16]. A
separate study would be required to elucidate the role of all
the various birth control methods as they inﬂuence cervical
dysplasia discrepancies over time.
5. Conclusions
To our knowledge, this is the ﬁrst study that examines
the eﬀect of time on histologic grade of CIN in the
LEEP specimen when LEEP is performed for discrepancy.
Research demonstrates that the neoplasia caused by HPV
may regress spontaneously with time [4, 5]. Hence, we
sought to determine whether the length of time between
the initial HGSIL Pap smear and a LEEP performed for
discrepant pathology on cervical biopsy aﬀectsthe pathology
results of the LEEP specimen. We demonstrated a trend
suggesting that, when LEEP is performed more than 5
months from the initial HGSIL Pap smear, isolating CIN 2,3
in the LEEP specimen is less likely. This trend was more
pronounced in the multivariate regression controlling for
birth control method, suggesting that birth control method
may impact regression of HPV. When controlling for birth
control method, the trend toward decrease in CIN 2,3 with
time was more clear as there were more women using Depo-
Provera who had CIN 2,3 and had their LEEP greater than
ﬁve months from their HGSIL Pap smear.
Many have explored the option of “See-and-Treat”
for HGSIL management with immediate LEEP in recent
years. The 2006 ASCCP Guidelines advocate caution and
observation rather than an immediate excisional procedure
in women who are still considering childbearing due to the
increased pregnancy complications [3]. We cannot directly
extrapolate our data into the risk of overtreatment with
immediate LEEP. Whenever colposcopy is performed, one
must also take into account the immunological stimulation
that is thought to accompany colposcopic biopsy of cervical
neoplasia that hastens resolution [17]. In this study alone
if all patients went to an immediate LEEP, at most 45%
of women may have had CIN 1 or less on LEEP and
would have been overtreated. Some studies have shown a
much lower overtreatment rate when the time interval from
Pap to LEEP is diminished [18, 19]. However, it would be
diﬃcult to advocate for immediate LEEP in our patient
population based on the percentages of this study. Given
the propensity of HPV clearance over time, a “see-and-treat”
approach deserves scrutiny. This study suggests that, when in
adiscrepantsituation,thevariableoftimebetweentheinitial
HGSIL Pap and LEEP may be a consideration in determining
whether a LEEP is appropriate.
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